25 XP   0   0   10

ARCA Biopharma Inc
Buy, Hold or Sell?

Let's analyse ARCA Biopharma Inc together

PenkeI guess you are interested in ARCA Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ARCA Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about ARCA Biopharma Inc

I send you an email if I find something interesting about ARCA Biopharma Inc.

Quick analysis of ARCA Biopharma Inc (30 sec.)










What can you expect buying and holding a share of ARCA Biopharma Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.55
Expected worth in 1 year
$2.23
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
$-0.32
Return On Investment
-9.4%

For what price can you sell your share?

Current Price per Share
$3.40
Expected price per share
$2.3199 - $3.88
How sure are you?
50%

1. Valuation of ARCA Biopharma Inc (5 min.)




Live pricePrice per Share (EOD)

$3.40

Intrinsic Value Per Share

$-5.22 - $1.13

Total Value Per Share

$-2.66 - $3.68

2. Growth of ARCA Biopharma Inc (5 min.)




Is ARCA Biopharma Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$37m$44.3m-$5.6m-14.6%

How much money is ARCA Biopharma Inc making?

Current yearPrevious yearGrowGrow %
Making money-$1m-$2.3m$1.2m112.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of ARCA Biopharma Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#516 / 1016

Most Revenue
#908 / 1016

Most Profit
#245 / 1016

Most Efficient
#355 / 1016

What can you expect buying and holding a share of ARCA Biopharma Inc? (5 min.)

Welcome investor! ARCA Biopharma Inc's management wants to use your money to grow the business. In return you get a share of ARCA Biopharma Inc.

What can you expect buying and holding a share of ARCA Biopharma Inc?

First you should know what it really means to hold a share of ARCA Biopharma Inc. And how you can make/lose money.

Speculation

The Price per Share of ARCA Biopharma Inc is $3.4. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of ARCA Biopharma Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in ARCA Biopharma Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.55. Based on the TTM, the Book Value Change Per Share is $-0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.16 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of ARCA Biopharma Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.08-2.2%-0.09-2.7%-0.17-5.0%-0.17-5.0%-0.20-5.8%
Usd Book Value Change Per Share-0.07-1.9%-0.08-2.4%-0.16-4.8%0.113.1%0.041.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.07-1.9%-0.08-2.4%-0.16-4.8%0.113.1%0.041.1%
Usd Price Per Share1.70-1.93-2.31-3.29-2.61-
Price to Earnings Ratio-5.66--5.28--4.01--6.83--4.49-
Price-to-Total Gains Ratio-26.00--24.25--17.21--20.83--15.09-
Price to Book Ratio0.67-0.72-0.76-2.96-2.14-
Price-to-Total Gains Ratio-26.00--24.25--17.21--20.83--15.09-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.4
Number of shares294
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.080.11
Usd Total Gains Per Share-0.080.11
Gains per Quarter (294 shares)-23.5831.41
Gains per Year (294 shares)-94.34125.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-94-1040126116
20-189-1980251242
30-283-2920377368
40-377-3860503494
50-472-4800628620
60-566-5740754746
70-660-6680880872
80-755-76201005998
90-849-856011311124
100-943-950012571250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.040.00.00.0%3.0105.00.02.8%
Book Value Change Per Share0.04.00.00.0%1.011.00.08.3%5.015.00.025.0%8.032.00.020.0%24.082.02.022.2%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%2.00.0106.01.9%
Total Gains per Share0.04.00.00.0%1.011.00.08.3%5.015.00.025.0%8.032.00.020.0%24.082.02.022.2%

Fundamentals of ARCA Biopharma Inc

About ARCA Biopharma Inc

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Fundamental data was last updated by Penke on 2024-04-09 07:48:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of ARCA Biopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit ARCA Biopharma Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare ARCA Biopharma Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ARCA Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--199.6%+199.6%
TTM--213.0%+213.0%
YOY--279.3%+279.3%
5Y--438.4%+438.4%
10Y--605.5%+605.5%
1.1.2. Return on Assets

Shows how efficient ARCA Biopharma Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare ARCA Biopharma Inc to the Biotechnology industry mean.
  • -2.9% Return on Assets means that ARCA Biopharma Inc generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ARCA Biopharma Inc:

  • The MRQ is -2.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -2.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.9%TTM-2.7%-0.1%
TTM-2.7%YOY-4.8%+2.1%
TTM-2.7%5Y-8.2%+5.4%
5Y-8.2%10Y-12.7%+4.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.9%-13.5%+10.6%
TTM-2.7%-12.9%+10.2%
YOY-4.8%-11.8%+7.0%
5Y-8.2%-14.1%+5.9%
10Y-12.7%-16.0%+3.3%
1.1.3. Return on Equity

Shows how efficient ARCA Biopharma Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare ARCA Biopharma Inc to the Biotechnology industry mean.
  • -2.9% Return on Equity means ARCA Biopharma Inc generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ARCA Biopharma Inc:

  • The MRQ is -2.9%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -2.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.9%TTM-2.8%-0.1%
TTM-2.8%YOY-5.1%+2.3%
TTM-2.8%5Y-9.1%+6.2%
5Y-9.1%10Y-14.2%+5.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.9%-16.9%+14.0%
TTM-2.8%-16.1%+13.3%
YOY-5.1%-15.1%+10.0%
5Y-9.1%-19.9%+10.8%
10Y-14.2%-20.9%+6.7%

1.2. Operating Efficiency of ARCA Biopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient ARCA Biopharma Inc is operating .

  • Measures how much profit ARCA Biopharma Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare ARCA Biopharma Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ARCA Biopharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--295.1%+295.1%
TTM--225.8%+225.8%
YOY--288.4%+288.4%
5Y--477.4%+477.4%
10Y--625.6%+625.6%
1.2.2. Operating Ratio

Measures how efficient ARCA Biopharma Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ARCA Biopharma Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.090-3.090
TTM-3.264-3.264
YOY-3.783-3.783
5Y-5.679-5.679
10Y-7.894-7.894

1.3. Liquidity of ARCA Biopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if ARCA Biopharma Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 59.01 means the company has $59.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ARCA Biopharma Inc:

  • The MRQ is 59.014. The company is very able to pay all its short-term debts. +2
  • The TTM is 39.150. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ59.014TTM39.150+19.864
TTM39.150YOY24.068+15.082
TTM39.1505Y21.248+17.902
5Y21.24810Y17.604+3.645
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ59.0143.914+55.100
TTM39.1504.220+34.930
YOY24.0685.388+18.680
5Y21.2486.045+15.203
10Y17.6046.406+11.198
1.3.2. Quick Ratio

Measures if ARCA Biopharma Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare ARCA Biopharma Inc to the Biotechnology industry mean.
  • A Quick Ratio of 58.76 means the company can pay off $58.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ARCA Biopharma Inc:

  • The MRQ is 58.761. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 38.723. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ58.761TTM38.723+20.038
TTM38.723YOY23.689+15.034
TTM38.7235Y20.855+17.868
5Y20.85510Y18.149+2.705
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ58.7613.572+55.189
TTM38.7233.998+34.725
YOY23.6895.390+18.299
5Y20.8555.969+14.886
10Y18.1496.287+11.862

1.4. Solvency of ARCA Biopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of ARCA Biopharma Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare ARCA Biopharma Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.02 means that ARCA Biopharma Inc assets are financed with 2.2% credit (debt) and the remaining percentage (100% - 2.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ARCA Biopharma Inc:

  • The MRQ is 0.022. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.034. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.022TTM0.034-0.011
TTM0.034YOY0.052-0.018
TTM0.0345Y0.072-0.039
5Y0.07210Y0.081-0.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0220.336-0.314
TTM0.0340.334-0.300
YOY0.0520.269-0.217
5Y0.0720.366-0.294
10Y0.0810.390-0.309
1.4.2. Debt to Equity Ratio

Measures if ARCA Biopharma Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare ARCA Biopharma Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 2.3% means that company has $0.02 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ARCA Biopharma Inc:

  • The MRQ is 0.023. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.035. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.023TTM0.035-0.012
TTM0.035YOY0.055-0.020
TTM0.0355Y0.080-0.045
5Y0.08010Y0.090-0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0230.382-0.359
TTM0.0350.396-0.361
YOY0.0550.335-0.280
5Y0.0800.434-0.354
10Y0.0900.465-0.375

2. Market Valuation of ARCA Biopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings ARCA Biopharma Inc generates.

  • Above 15 is considered overpriced but always compare ARCA Biopharma Inc to the Biotechnology industry mean.
  • A PE ratio of -5.66 means the investor is paying $-5.66 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ARCA Biopharma Inc:

  • The EOD is -11.319. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.659. Based on the earnings, the company is expensive. -2
  • The TTM is -5.277. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.319MRQ-5.659-5.659
MRQ-5.659TTM-5.277-0.382
TTM-5.277YOY-4.009-1.268
TTM-5.2775Y-6.829+1.552
5Y-6.82910Y-4.487-2.342
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.319-2.259-9.060
MRQ-5.659-2.569-3.090
TTM-5.277-2.664-2.613
YOY-4.009-4.120+0.111
5Y-6.829-6.258-0.571
10Y-4.487-6.171+1.684
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ARCA Biopharma Inc:

  • The EOD is -11.672. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.836. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.332. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-11.672MRQ-5.836-5.836
MRQ-5.836TTM-6.332+0.496
TTM-6.332YOY-3.531-2.802
TTM-6.3325Y-7.688+1.356
5Y-7.68810Y-5.014-2.674
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-11.672-2.924-8.748
MRQ-5.836-3.246-2.590
TTM-6.332-3.488-2.844
YOY-3.531-5.620+2.089
5Y-7.688-8.315+0.627
10Y-5.014-8.826+3.812
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of ARCA Biopharma Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.67 means the investor is paying $0.67 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ARCA Biopharma Inc:

  • The EOD is 1.332. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.666. Based on the equity, the company is cheap. +2
  • The TTM is 0.724. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.332MRQ0.666+0.666
MRQ0.666TTM0.724-0.058
TTM0.724YOY0.756-0.032
TTM0.7245Y2.958-2.234
5Y2.95810Y2.137+0.821
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.3321.851-0.519
MRQ0.6662.090-1.424
TTM0.7242.095-1.371
YOY0.7562.844-2.088
5Y2.9583.466-0.508
10Y2.1373.815-1.678
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ARCA Biopharma Inc.

3.1. Institutions holding ARCA Biopharma Inc

Institutions are holding 51.564% of the shares of ARCA Biopharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Cable Car Capital LLC27.58717.0612400045240004520
2023-12-31Western Standard LLC9.72441.5961141014323587320.0868
2023-12-31BML Capital Management LLC4.8750.910370693000
2023-12-31Vanguard Group Inc3.128045359830630.6799
2023-12-31Newtyn Management LLC1.85720.0899269320-30680-10.2267
2023-12-31BlackRock Inc1.59930231911-48-0.0207
2023-12-31Geode Capital Management, LLC0.9816014234900
2023-12-31State Street Corporation0.490607113700
2023-12-31Renaissance Technologies Corp0.39510.000257299649912.7933
2023-12-31Dimensional Fund Advisors, Inc.0.293204251400
2023-12-31abrdn PLC0.22390.000132461324610
2023-12-31Northern Trust Corp0.144702098200
2023-12-31Charles Schwab Investment Management Inc0.103401498800
2023-12-31TWO SIGMA SECURITIES, LLC0.08360.000212119121190
2023-12-31Tower Research Capital LLC0.02080.00013023-668-18.0981
2023-12-31UBS Group AG0.0078011311006804.8
2023-12-31Parallel Advisors, LLC0.0017024400
2023-12-31SIMPLEX TRADING, LLC0.000701001000
2023-12-31Wells Fargo & Co0.000507945.3333
2023-12-31Royal Bank of Canada0.0004056-7-11.1111
Total 51.5199.65817470836+4260174+57.0%

3.2. Funds holding ARCA Biopharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.1527031216600
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.97530.000214143200
2024-02-29Fidelity Total Market Index0.36520.00015295900
2024-02-29Fidelity Extended Market Index0.28870.000241859-203-0.4826
2024-02-29abrdn Life Sciences Investors0.22390.0123246100
2024-02-29DFA US Micro Cap I0.22340.00073240000
2024-02-29Fidelity Nasdaq Composite Index0.17320.00032511600
2024-02-29Schwab Total Stock Market Index0.10340.00011498800
2024-02-29Fidelity Series Total Market Index0.102701489700
2023-12-31NT Ext Equity Mkt Idx Fd - L0.0810.00031174200
2023-12-31Northern Trust Extended Eq Market Idx0.0810.00031174200
2023-12-31SSgA U.S. Extended Market Index Class I0.07880.00071143000
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.05730.0002830300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.0460.00026668130.1953
2024-03-29Dimensional US Targeted Value ETF0.03560.0001516200
2024-02-29Spartan Total Market Index Pool E0.02980431900
2023-12-31SSgA U.S. Total Market Index Strategy0.02270.00013297-76-2.2532
2024-02-29Spartan Extended Market Index Pool E0.02170.000231402036.9118
2024-02-29State St US Ttl Mkt Indx SL Cl I0.01170170000
2023-12-31Northern Trust Wilshire 50000.00650.000193700
Total 5.08060.0158736718-630.0%

3.3. Insider Transactions

Insiders are holding 1.29% of the shares of ARCA Biopharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-05-25Fund Lp FunicularBUY648512.32
2022-05-23Fund Lp FunicularBUY23012.29
2022-05-18Fund Lp FunicularBUY130722.3
2022-05-16Fund Lp FunicularBUY429142.3
2022-05-13Fund Lp FunicularBUY140002.29
2022-05-11Fund Lp FunicularBUY245962.29
2022-05-09Fund Lp FunicularBUY492212.27
2022-05-05Fund Lp FunicularBUY169032.27
2022-05-02Fund Lp FunicularBUY12592.31
2022-04-28Fund Lp FunicularBUY233812.32
2022-04-25Fund Lp FunicularBUY137512.29
2022-04-18Fund Lp FunicularBUY91192.31
2022-04-14Fund Lp FunicularBUY174102.33
2022-04-11Fund Lp FunicularBUY46552.31
2022-04-08Fund Lp FunicularBUY306602.31
2022-04-06Fund Lp FunicularBUY268062.3
2022-04-04Fund Lp FunicularBUY1223422.26
2021-11-22Christopher David OzeroffBUY500002.26
2021-05-12Robert E ConwayBUY100003.19
2021-05-05Robert E ConwayBUY100003.23

4. Summary

4.1. Key Performance Indicators

The key performance indicators of ARCA Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.065-0.080+23%-0.162+147%0.107-161%0.037-277%
Book Value Per Share--2.5532.668-4%3.057-16%2.460+4%1.942+31%
Current Ratio--59.01439.150+51%24.068+145%21.248+178%17.604+235%
Debt To Asset Ratio--0.0220.034-34%0.052-57%0.072-69%0.081-73%
Debt To Equity Ratio--0.0230.035-35%0.055-59%0.080-72%0.090-75%
Dividend Per Share----0%-0%-0%-0%
Eps---0.075-0.092+23%-0.169+125%-0.171+128%-0.196+161%
Free Cash Flow Per Share---0.073-0.086+19%-0.188+158%-0.163+124%-0.186+156%
Free Cash Flow To Equity Per Share---0.073-0.086+19%-0.188+158%0.284-126%0.135-154%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--1.131--------
Intrinsic Value_10Y_min---5.217--------
Intrinsic Value_1Y_max---0.621--------
Intrinsic Value_1Y_min---0.756--------
Intrinsic Value_3Y_max---1.307--------
Intrinsic Value_3Y_min---2.084--------
Intrinsic Value_5Y_max---1.317--------
Intrinsic Value_5Y_min---3.194--------
Market Cap49303740.000+50%24651943.10028023394.025-12%33425035.500-26%47704417.336-48%37814085.265-35%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio1.332+50%0.6660.724-8%0.756-12%2.958-77%2.137-69%
Pe Ratio-11.319-100%-5.659-5.277-7%-4.009-29%-6.829+21%-4.487-21%
Price Per Share3.400+50%1.7001.933-12%2.305-26%3.290-48%2.608-35%
Price To Free Cash Flow Ratio-11.672-100%-5.836-6.332+9%-3.531-40%-7.688+32%-5.014-14%
Price To Total Gains Ratio-52.002-100%-26.001-24.247-7%-17.211-34%-20.831-20%-15.087-42%
Quick Ratio--58.76138.723+52%23.689+148%20.855+182%18.149+224%
Return On Assets---0.029-0.027-5%-0.048+68%-0.082+185%-0.127+341%
Return On Equity---0.029-0.028-4%-0.051+74%-0.091+209%-0.142+382%
Total Gains Per Share---0.065-0.080+23%-0.162+147%0.107-161%0.037-277%
Usd Book Value--37020000.00038689250.000-4%44325250.000-16%35666050.000+4%28156725.000+31%
Usd Book Value Change Per Share---0.065-0.080+23%-0.162+147%0.107-161%0.037-277%
Usd Book Value Per Share--2.5532.668-4%3.057-16%2.460+4%1.942+31%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.075-0.092+23%-0.169+125%-0.171+128%-0.196+161%
Usd Free Cash Flow---1056000.000-1253500.000+19%-2728500.000+158%-2364100.000+124%-2699350.000+156%
Usd Free Cash Flow Per Share---0.073-0.086+19%-0.188+158%-0.163+124%-0.186+156%
Usd Free Cash Flow To Equity Per Share---0.073-0.086+19%-0.188+158%0.284-126%0.135-154%
Usd Market Cap49303740.000+50%24651943.10028023394.025-12%33425035.500-26%47704417.336-48%37814085.265-35%
Usd Price Per Share3.400+50%1.7001.933-12%2.305-26%3.290-48%2.608-35%
Usd Profit---1089000.000-1091750.000+0%-2314000.000+112%-2408250.000+121%-2804150.000+157%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.065-0.080+23%-0.162+147%0.107-161%0.037-277%
 EOD+5 -3MRQTTM+19 -10YOY+22 -75Y+17 -1210Y+19 -10

4.2. Fundamental Score

Let's check the fundamental score of ARCA Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-11.319
Price to Book Ratio (EOD)Between0-11.332
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than158.761
Current Ratio (MRQ)Greater than159.014
Debt to Asset Ratio (MRQ)Less than10.022
Debt to Equity Ratio (MRQ)Less than10.023
Return on Equity (MRQ)Greater than0.15-0.029
Return on Assets (MRQ)Greater than0.05-0.029
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of ARCA Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5079.768
Ma 20Greater thanMa 502.683
Ma 50Greater thanMa 1002.074
Ma 100Greater thanMa 2001.889
OpenGreater thanClose3.260
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets37,861
Total Liabilities841
Total Stockholder Equity37,020
 As reported
Total Liabilities 841
Total Stockholder Equity+ 37,020
Total Assets = 37,861

Assets

Total Assets37,861
Total Current Assets37,592
Long-term Assets269
Total Current Assets
Cash And Cash Equivalents 37,431
Other Current Assets 161
Total Current Assets  (as reported)37,592
Total Current Assets  (calculated)37,592
+/-0
Long-term Assets
Property Plant Equipment 257
Long-term Assets Other 12
Long-term Assets  (as reported)269
Long-term Assets  (calculated)269
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities637
Long-term Liabilities204
Total Stockholder Equity37,020
Total Current Liabilities
Short-term Debt 76
Accounts payable 362
Other Current Liabilities 275
Total Current Liabilities  (as reported)637
Total Current Liabilities  (calculated)713
+/- 76
Long-term Liabilities
Capital Lease Obligations 204
Long-term Liabilities  (as reported)204
Long-term Liabilities  (calculated)204
+/-0
Total Stockholder Equity
Common Stock14
Retained Earnings -188,741
Other Stockholders Equity 225,747
Total Stockholder Equity (as reported)37,020
Total Stockholder Equity (calculated)37,020
+/-0
Other
Capital Stock14
Cash and Short Term Investments 37,431
Common Stock Shares Outstanding 14,501
Current Deferred Revenue-76
Liabilities and Stockholders Equity 37,861
Net Debt -37,227
Net Invested Capital 37,020
Net Working Capital 36,955
Property Plant and Equipment Gross 469
Short Long Term Debt Total 204



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-311997-12-311997-09-301997-06-301997-03-31
> Total Assets 
7,500
17,800
69,000
67,000
64,400
61,500
56,000
57,900
52,600
47,400
45,100
45,400
43,772
38,217
31,227
21,288
21,288
28,622
39,823
39,904
39,904
36,850
32,143
27,072
69,018
49,035
43,828
57,809
119,725
108,490
100,339
79,264
134,116
123,718
112,559
108,046
248,092
231,286
212,105
184,405
158,896
154,789
135,403
120,683
103,686
87,018
75,399
66,045
51,750
39,821
18,675
9,372
13,405
11,693
9,498
8,156
6,344
8,581
6,498
6,502
4,958
3,816
3,462
3,212
4,139
20,783
19,138
17,084
22,655
20,540
18,039
16,132
13,261
45,115
42,397
39,574
36,928
32,635
28,679
24,629
20,589
17,296
16,921
12,365
12,788
10,067
8,445
6,825
8,606
10,388
9,949
8,536
7,461
11,633
51,982
50,429
69,183
65,338
60,192
54,924
51,014
48,101
44,965
43,085
42,059
41,083
39,184
37,861
37,86139,18441,08342,05943,08544,96548,10151,01454,92460,19265,33869,18350,42951,98211,6337,4618,5369,94910,3888,6066,8258,44510,06712,78812,36516,92117,29620,58924,62928,67932,63536,92839,57442,39745,11513,26116,13218,03920,54022,65517,08419,13820,7834,1393,2123,4623,8164,9586,5026,4988,5816,3448,1569,49811,69313,4059,37218,67539,82151,75066,04575,39987,018103,686120,683135,403154,789158,896184,405212,105231,286248,092108,046112,559123,718134,11679,264100,339108,490119,72557,80943,82849,03569,01827,07232,14336,85039,90439,90439,82328,62221,28821,28831,22738,21743,77245,40045,10047,40052,60057,90056,00061,50064,40067,00069,00017,8007,500
   > Total Current Assets 
5,300
14,400
65,200
60,200
56,600
52,800
46,300
48,200
42,300
36,800
33,300
33,000
31,950
24,643
15,961
5,627
5,627
10,432
20,326
16,301
16,301
14,891
12,013
5,882
45,093
29,288
24,089
39,857
102,784
92,496
85,600
65,995
121,276
105,870
90,779
85,765
225,604
208,779
189,241
166,335
141,409
138,950
114,140
99,986
83,460
71,976
60,917
52,128
36,944
25,273
11,447
8,285
12,403
10,777
8,670
7,162
5,455
7,827
6,088
6,212
4,702
3,590
3,265
3,045
3,993
20,658
19,011
16,925
21,801
19,680
17,465
15,488
12,674
44,327
41,687
38,916
31,018
26,735
23,788
21,445
19,854
16,655
16,376
12,299
12,727
10,010
8,392
6,777
8,519
10,323
9,904
8,480
7,378
11,573
51,936
49,968
68,730
64,793
59,666
54,421
50,539
47,655
44,550
42,699
41,702
40,755
38,892
37,592
37,59238,89240,75541,70242,69944,55047,65550,53954,42159,66664,79368,73049,96851,93611,5737,3788,4809,90410,3238,5196,7778,39210,01012,72712,29916,37616,65519,85421,44523,78826,73531,01838,91641,68744,32712,67415,48817,46519,68021,80116,92519,01120,6583,9933,0453,2653,5904,7026,2126,0887,8275,4557,1628,67010,77712,4038,28511,44725,27336,94452,12860,91771,97683,46099,986114,140138,950141,409166,335189,241208,779225,60485,76590,779105,870121,27665,99585,60092,496102,78439,85724,08929,28845,0935,88212,01314,89116,30116,30120,32610,4325,6275,62715,96124,64331,95033,00033,30036,80042,30048,20046,30052,80056,60060,20065,20014,4005,300
       Cash And Cash Equivalents 
4,700
13,900
39,400
23,200
32,700
11,500
10,600
21,600
16,400
17,300
16,400
13,700
25,434
14,657
11,843
2,699
2,699
6,341
16,534
12,329
12,329
11,834
4,272
2,225
25,286
20,542
13,856
13,141
80,642
19,267
1,986
16,811
66,968
47,930
33,550
37,764
166,010
134,786
102,055
60,335
66,855
40,321
45,128
32,061
37,968
42,714
35,168
35,891
25,920
19,014
10,642
7,763
4,627
9,917
7,906
7,025
5,085
7,463
5,748
5,943
4,227
3,182
3,081
2,920
3,537
20,374
18,632
16,756
21,202
19,377
17,249
15,354
12,184
44,086
41,482
38,802
29,717
14,379
8,095
7,401
6,170
9,101
8,142
8,702
12,096
9,635
8,056
6,608
8,006
9,966
9,645
8,363
6,674
11,041
51,095
49,071
66,933
63,197
58,313
53,359
49,059
46,437
43,939
42,445
40,850
40,156
38,487
37,431
37,43138,48740,15640,85042,44543,93946,43749,05953,35958,31363,19766,93349,07151,09511,0416,6748,3639,6459,9668,0066,6088,0569,63512,0968,7028,1429,1016,1707,4018,09514,37929,71738,80241,48244,08612,18415,35417,24919,37721,20216,75618,63220,3743,5372,9203,0813,1824,2275,9435,7487,4635,0857,0257,9069,9174,6277,76310,64219,01425,92035,89135,16842,71437,96832,06145,12840,32166,85560,335102,055134,786166,01037,76433,55047,93066,96816,8111,98619,26780,64213,14113,85620,54225,2862,2254,27211,83412,32912,32916,5346,3412,6992,69911,84314,65725,43413,70016,40017,30016,40021,60010,60011,50032,70023,20039,40013,9004,700
       Short-term Investments 
0
0
0
0
0
0
0
0
0
17,500
13,500
17,000
4,481
7,732
1,470
0
0
0
0
0
0
0
0
0
15,979
6,034
4,512
21,048
13,384
60,728
68,685
33,814
39,724
43,968
41,980
32,572
34,264
44,781
55,143
92,791
67,951
79,830
66,126
65,506
43,200
27,333
23,964
15,081
9,368
5,026
0
0
0
223
222
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
910
11,979
15,373
13,762
13,041
6,906
7,809
3,050
3,050
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000003,0503,0507,8096,90613,04113,76215,37311,9799100000000000000000000002222230005,0269,36815,08123,96427,33343,20065,50666,12679,83067,95192,79155,14344,78134,26432,57241,98043,96839,72433,81468,68560,72813,38421,0484,5126,03415,9790000000001,4707,7324,48117,00013,50017,500000000000
       Net Receivables 
300
100
2,400
2,200
600
3,300
2,500
700
3,400
900
2,400
1,300
1,499
1,623
115
22
22
717
22
1,090
1,090
363
183
632
585
355
112
341
341
0
0
271
36
66
53
72
59
7,803
8,169
8,559
3,311
16,387
430
588
834
1,080
835
441
441
0
0
0
6,848
0
0
0
0
264
244
224
204
183
164
144
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000014416418320422424426400006,8480004414418351,08083458843016,3873,3118,5598,1697,8035972536636271003413411123555856321833631,0901,0902271722221151,6231,4991,3002,4009003,4007002,5003,3006002,2002,400100300
       Other Current Assets 
300
400
23,400
34,800
23,300
38,000
33,200
25,900
22,500
1,100
1,000
1,000
536
631
2,533
0
2,906
3,374
3,770
0
992
2,694
7,558
3,025
3,243
2,357
2,364
5,327
1,463
2,432
14,929
2,462
3,013
2,678
3,538
3,096
10,699
3,389
5,438
4,650
3,292
2,412
2,456
1,831
1,458
849
950
715
1,656
1,233
805
522
928
637
542
137
370
364
340
269
475
408
184
125
456
284
379
169
599
303
216
134
490
241
205
114
391
377
320
282
643
648
425
547
631
375
336
169
513
357
259
117
704
532
841
897
1,797
1,596
1,353
1,062
1,480
1,218
611
254
852
599
405
161
1614055998522546111,2181,4801,0621,3531,5961,7978978415327041172593575131693363756315474256486432823203773911142052414901342163035991693792844561251844084752693403643701375426379285228051,2331,6567159508491,4581,8312,4562,4123,2924,6505,4383,38910,6993,0963,5382,6783,0132,46214,9292,4321,4635,3272,3642,3573,2433,0257,5582,69499203,7703,3742,90602,5336315361,0001,0001,10022,50025,90033,20038,00023,30034,80023,400400300
   > Long-term Assets 
2,200
3,400
3,800
6,800
7,800
8,700
9,700
9,700
10,300
10,600
11,800
12,400
11,822
13,574
15,266
0
15,661
18,190
19,497
0
23,603
21,959
20,130
21,190
23,925
19,747
19,739
17,952
16,941
15,994
14,739
13,269
12,840
17,848
21,780
22,281
22,488
22,507
22,864
18,070
17,487
15,839
21,263
20,697
20,226
15,042
14,482
13,917
14,806
14,548
7,228
1,087
1,002
916
828
994
889
754
410
290
256
226
197
167
146
125
127
159
854
860
574
644
587
788
710
658
5,910
5,900
4,891
3,184
735
641
545
66
61
57
53
48
87
65
45
56
83
60
46
461
453
545
526
503
475
446
415
386
357
328
292
269
2692923283573864154464755035265454534614660835645658748535761665456417353,1844,8915,9005,9106587107885876445748608541591271251461671972262562904107548899948289161,0021,0877,22814,54814,80613,91714,48215,04220,22620,69721,26315,83917,48718,07022,86422,50722,48822,28121,78017,84812,84013,26914,73915,99416,94117,95219,73919,74723,92521,19020,13021,95923,603019,49718,19015,661015,26613,57411,82212,40011,80010,60010,3009,7009,7008,7007,8006,8003,8003,4002,200
       Property Plant Equipment 
1,700
2,400
3,200
3,900
5,000
5,900
6,900
6,900
7,500
7,800
8,900
8,400
9,241
11,000
12,058
12,465
12,465
14,703
16,517
18,988
18,988
17,572
16,357
15,142
17,058
14,979
10,965
9,955
9,148
8,401
7,655
6,048
5,571
10,202
14,481
15,165
15,011
14,942
15,768
11,978
11,607
10,002
9,461
8,906
8,445
7,940
7,383
6,833
1,628
1,376
1,145
1,026
941
855
771
690
605
490
166
66
52
43
33
23
22
21
27
29
26
29
26
36
34
34
31
28
24
76
69
66
59
54
48
42
37
33
29
24
63
41
21
32
59
36
10
449
441
527
508
485
457
428
397
368
339
310
280
257
2572803103393683974284574855085274414491036593221416324293337424854596669762428313434362629262927212223334352661664906056907718559411,0261,1451,3761,6286,8337,3837,9408,4458,9069,46110,00211,60711,97815,76814,94215,01115,16514,48110,2025,5716,0487,6558,4019,1489,95510,96514,97917,05815,14216,35717,57218,98818,98816,51714,70312,46512,46512,05811,0009,2418,4008,9007,8007,5006,9006,9005,9005,0003,9003,2002,4001,700
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
4,671
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000000000004,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,6714,67100000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,306
5,008
3,967
2,352
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000002,3523,9675,0085,3060000000000000000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
500
1,000
600
700
700
700
700
700
700
800
800
1,800
475
468
1,102
1,090
1,090
1,381
1,374
3,009
3,009
2,781
2,667
2,142
2,211
2,156
6,764
7,496
7,292
7,092
6,892
7,030
7,078
7,455
7,299
7,116
2,806
2,894
2,425
0
0
0
0
4,671
0
0
0
0
0
6,000
6,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000000000000006,0006,000000004,67100002,4252,8942,8067,1167,2997,4557,0787,0306,8927,0927,2927,4966,7642,1562,2112,1422,6672,7813,0093,0091,3741,3811,0901,0901,1024684751,8008008007007007007007007006001,000500
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
11,791
0
0
0
7,084
13,178
13,172
6,083
61
61
61
57
304
284
264
244
224
204
183
164
144
124
104
100
130
828
831
548
608
553
754
679
630
5,886
5,824
4,822
3,118
676
587
497
24
24
24
24
24
24
24
24
24
24
24
0
440
12
18
18
18
0
18
0
18
18
0
0
0
0001818018018181812440024242424242424242424244975876763,1184,8225,8245,886630679754553608548831828130100104124144164183204224244264284304576161616,08313,17213,1787,08400011,7910000000000000000000000000000000000000000000
> Total Liabilities 
1,900
3,500
4,800
4,100
4,000
4,300
4,200
10,300
9,700
9,000
10,900
16,200
20,698
20,101
16,629
12,926
12,926
14,882
15,143
24,371
24,371
23,791
20,453
31,636
38,437
33,775
38,943
35,108
41,075
40,916
41,823
33,675
34,259
40,677
48,512
51,282
94,244
90,889
92,751
114,562
102,018
65,969
57,977
53,024
52,063
34,672
30,684
23,537
26,427
22,564
5,155
1,960
1,367
1,233
1,031
1,385
1,701
1,036
686
770
602
529
286
305
828
750
769
1,503
1,121
1,219
841
1,391
1,134
1,357
1,304
1,504
2,344
1,744
2,199
2,435
2,553
2,549
2,569
2,090
1,734
1,069
982
793
1,288
1,199
1,150
926
1,155
1,328
1,527
3,908
3,274
4,130
3,592
3,881
3,076
3,138
2,238
1,412
1,528
1,845
1,216
841
8411,2161,8451,5281,4122,2383,1383,0763,8813,5924,1303,2743,9081,5271,3281,1559261,1501,1991,2887939821,0691,7342,0902,5692,5492,5532,4352,1991,7442,3441,5041,3041,3571,1341,3918411,2191,1211,5037697508283052865296027706861,0361,7011,3851,0311,2331,3671,9605,15522,56426,42723,53730,68434,67252,06353,02457,97765,969102,018114,56292,75190,88994,24451,28248,51240,67734,25933,67541,82340,91641,07535,10838,94333,77538,43731,63620,45323,79124,37124,37115,14314,88212,92612,92616,62920,10120,69816,20010,9009,0009,70010,3004,2004,3004,0004,1004,8003,5001,900
   > Total Current Liabilities 
1,300
2,700
4,000
3,400
3,400
3,800
3,500
5,900
5,500
4,300
5,700
10,900
15,962
14,173
11,296
8,204
8,204
11,428
12,232
18,018
18,018
18,072
15,164
26,610
31,889
25,162
30,839
14,085
26,697
27,548
31,937
22,613
23,240
30,396
39,299
44,915
41,485
40,083
36,966
43,839
34,036
27,580
21,405
18,187
32,189
16,530
14,345
11,346
14,766
19,247
2,467
1,644
1,081
976
805
1,190
1,538
1,004
661
754
594
529
286
305
828
750
769
1,502
1,120
1,217
838
1,388
1,133
1,356
1,304
1,504
2,344
1,697
2,156
2,396
2,518
2,519
2,544
2,070
1,719
1,060
978
793
1,288
1,199
1,150
926
1,155
1,328
1,527
3,499
2,880
3,695
3,182
3,498
2,719
2,809
1,937
1,132
1,266
1,602
992
637
6379921,6021,2661,1321,9372,8092,7193,4983,1823,6952,8803,4991,5271,3281,1559261,1501,1991,2887939781,0601,7192,0702,5442,5192,5182,3962,1561,6972,3441,5041,3041,3561,1331,3888381,2171,1201,5027697508283052865295947546611,0041,5381,1908059761,0811,6442,46719,24714,76611,34614,34516,53032,18918,18721,40527,58034,03643,83936,96640,08341,48544,91539,29930,39623,24022,61331,93727,54826,69714,08530,83925,16231,88926,61015,16418,07218,01818,01812,23211,4288,2048,20411,29614,17315,96210,9005,7004,3005,5005,9003,5003,8003,4003,4004,0002,7001,300
       Short-term Debt 
300
300
300
300
300
300
300
1,400
1,400
1,600
1,900
2,100
2,087
2,474
2,454
2,379
2,379
2,486
2,560
2,506
2,506
5,861
5,510
1,216
15,887
13,200
13,109
4,741
4,624
4,413
6,698
4,409
4,312
4,344
4,300
8,299
8,319
4,323
4,333
3,659
2,711
1,639
229
12,971
5,077
11,409
9,470
8,007
1,979
2,993
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60
0
0
0
0
0
0
2,993
0
435
410
0
0
106
108
103
95
86
77
76
767786951031081060041043502,99300000060000000000000000000000000000000000000002,9931,9798,0079,47011,4095,07712,9712291,6392,7113,6594,3334,3238,3198,2994,3004,3444,3124,4096,6984,4134,6244,74113,10913,20015,8871,2165,5105,8612,5062,5062,5602,4862,3792,3792,4542,4742,0872,1001,9001,6001,4001,400300300300300300300300
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
60
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000600000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
300
1,300
1,800
1,600
1,600
1,500
1,300
1,900
1,700
700
1,700
1,500
1,346
2,712
2,480
0
1,979
2,491
2,900
0
3,210
2,694
2,425
2,235
5,054
2,912
2,390
1,712
1,961
2,779
3,661
3,107
2,068
2,236
2,348
4,919
3,578
3,887
4,556
7,026
1,903
3,424
2,217
2,760
2,393
2,589
2,642
1,262
1,296
1,001
658
533
241
279
269
388
711
517
284
260
126
227
119
65
377
387
447
597
552
725
365
795
651
714
647
364
744
760
1,141
1,205
980
1,072
1,237
622
772
406
217
230
260
254
135
418
167
576
761
1,773
1,578
2,185
1,131
1,117
1,014
1,110
593
334
366
241
322
362
3623222413663345931,1101,0141,1171,1312,1851,5781,7737615761674181352542602302174067726221,2371,0729801,2051,141760744364647714651795365725552597447387377651192271262602845177113882692792415336581,0011,2961,2622,6422,5892,3932,7602,2173,4241,9037,0264,5563,8873,5784,9192,3482,2362,0683,1073,6612,7791,9611,7122,3902,9125,0542,2352,4252,6943,21002,9002,4911,97902,4802,7121,3461,5001,7007001,7001,9001,3001,5001,6001,6001,8001,300300
       Other Current Liabilities 
700
1,100
1,900
1,500
1,500
2,000
1,900
2,600
2,400
2,000
2,100
7,300
12,529
8,987
6,362
0
3,846
4,892
6,018
0
8,600
7,402
6,025
22,634
10,946
8,650
14,969
5,578
17,645
18,173
19,152
10,488
12,002
21,878
30,776
29,884
25,948
28,233
24,437
29,514
25,782
22,267
18,709
2,206
9,469
2,282
1,983
368
11,367
15,104
1,697
997
724
579
417
681
704
487
377
494
468
302
167
240
451
363
322
905
568
492
473
593
482
642
657
1,140
1,600
937
1,015
1,191
1,538
1,447
1,307
1,448
947
654
761
563
1,028
945
1,015
508
988
752
766
1,726
1,302
1,510
2,051
2,381
1,705
1,699
1,344
798
900
1,361
670
275
2756701,3619007981,3441,6991,7052,3812,0511,5101,3021,7267667529885081,0159451,0285637616549471,4481,3071,4471,5381,1911,0159371,6001,1406576424825934734925689053223634512401673024684943774877046814175797249971,69715,10411,3673681,9832,2829,4692,20618,70922,26725,78229,51424,43728,23325,94829,88430,77621,87812,00210,48819,15218,17317,6455,57814,9698,65010,94622,6346,0257,4028,60006,0184,8923,84606,3628,98712,5297,3002,1002,0002,4002,6001,9002,0001,5001,5001,9001,100700
   > Long-term Liabilities 
600
800
800
700
600
500
700
4,400
4,200
4,700
5,200
5,300
4,736
5,928
5,333
0
4,722
3,454
2,911
0
6,353
5,719
5,289
5,026
6,548
8,613
8,104
21,023
14,378
13,368
9,886
11,062
11,019
10,281
9,213
6,367
52,759
50,806
55,785
70,723
67,982
38,389
36,572
34,837
19,874
18,142
16,339
12,191
11,661
3,317
2,688
316
286
257
226
195
163
32
25
16
8
593,000
0
0
0
0
0
1
1
2
3
3
1
1
0
0
0
47
43
39
35
30
25
20
15
9
4
0
0
0
0
0
0
0
0
409
394
435
410
383
357
329
301
280
262
243
224
204
20422424326228030132935738341043539440900000000491520253035394347000113321100000593,00081625321631952262572863162,6883,31711,66112,19116,33918,14219,87434,83736,57238,38967,98270,72355,78550,80652,7596,3679,21310,28111,01911,0629,88613,36814,37821,0238,1048,6136,5485,0265,2895,7196,35302,9113,4544,72205,3335,9284,7365,3005,2004,7004,2004,400700500600700800800600
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,837
0
0
0
12,191
7,887
1,036
407
316
286
257
226
195
163
32
25
16
8
0
0
0
0
0
0
1
1
2
3
3
1
1
0
0
0
47
43
39
35
30
25
20
15
9
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000491520253035394347000113321100000081625321631952262572863164071,0367,88712,19100034,8370000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32
25
16
8
593,000
0
0
0
0
0
1
1
2
3
3
1
1
0
0
0
47
43
39
35
30
25
20
15
9
4
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000491520253035394347000113321100000593,0008162532000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
5,600
14,300
64,200
62,900
60,400
57,200
51,800
47,600
42,900
38,400
34,200
29,200
23,074
18,116
14,598
0
8,362
13,740
24,680
0
15,421
13,059
11,690
-4,564
30,581
15,260
4,885
22,701
78,650
67,574
58,516
45,589
99,857
83,041
64,047
56,764
153,848
140,397
119,354
69,843
56,878
88,820
77,426
67,659
51,623
52,346
44,715
42,508
25,323
17,257
13,520
7,412
12,038
10,460
8,467
6,771
4,643
7,545
5,812
5,732
4,356
3,287
3,176
2,907
3,311
20,033
18,369
15,581
21,534
19,321
17,198
14,741
12,127
43,758
41,093
38,070
34,584
30,891
26,480
22,194
18,036
14,747
14,352
10,275
11,054
8,998
7,463
6,032
7,318
9,189
8,799
7,610
6,306
10,305
50,455
46,521
65,909
61,208
56,600
51,043
47,938
44,963
42,727
41,673
40,531
39,238
37,968
37,020
37,02037,96839,23840,53141,67342,72744,96347,93851,04356,60061,20865,90946,52150,45510,3056,3067,6108,7999,1897,3186,0327,4638,99811,05410,27514,35214,74718,03622,19426,48030,89134,58438,07041,09343,75812,12714,74117,19819,32121,53415,58118,36920,0333,3112,9073,1763,2874,3565,7325,8127,5454,6436,7718,46710,46012,0387,41213,52017,25725,32342,50844,71552,34651,62367,65977,42688,82056,87869,843119,354140,397153,84856,76464,04783,04199,85745,58958,51667,57478,65022,7014,88515,26030,581-4,56411,69013,05915,421024,68013,7408,362014,59818,11623,07429,20034,20038,40042,90047,60051,80057,20060,40062,90064,20014,3005,600
   Common Stock
-14,800
-24,800
0
0
0
0
0
0
0
82,300
82,300
82,500
13
13
14
0
14
16
19
0
19
23
23
23
63
64
65
26
32
32
32
32
42
42
42
44
52
52
52
53
53
53
53
53
53
53
53
3
8
8
8
8
9
9
9
9
9
11
11
12
12
12
15
3
3
10
13
16
21
21
21
21
21
63
9
9
9
9
9
9
9
10
12
12
14
14
14
14
1
1
2
2
2
2
9
10
14
14
14
14
14
14
14
14
14
14
14
14
1414141414141414141414141092222111414141412121099999996321212121211613103315121212111199999888835353535353535353525252444242423232323226656463232323190191614014131382,50082,30082,3000000000-24,800-14,800
   Retained Earnings Total Equity0000000000-163,088-158,254-154,154-149,029-147,038-145,736-144,416-143,190-142,034-140,598-138,934-137,445-135,852-133,736-131,001-126,804-122,371-116,849-112,511-108,267-103,608-99,714-96,067-92,899-90,085-87,366-84,622-82,011-79,727-77,322-74,933-71,987-70,264-69,065-67,994-67,154-66,227-65,081-63,674-62,044-60,222000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
-600
-800
-1,000
-1,300
-1,700
-2,100
-2,600
-3,000
-3,500
-3,700
-3,600
-3,600
-56
-40
-26
-8,894
-8
-8,894
-8,894
-14,952
-53
-14,952
-18
-6
-79
9
-15
-45
-5
-307
-79
-206
-177
-111
1
-250
-178
436
594
10
-3
-11
5
49
88
12
-90
11
-33
-12
-646
-641
-728
-810
-894
-976
-1,043
-1,156
-1,475
-467
-481
-491
-501
-510
-486
-496
-482
-485
-488
-400
-378
-382
-386
-391
-384
-387
6
13
-6
-19
-9
-5
-3
-2
-407
-398
-403
-374
-379
-376
-381
-367
-370
-344
-260
0
-253
-212
0
0
0
0
0
0
0
0
0
0
0000000000-212-2530-260-344-370-367-381-376-379-374-403-398-407-2-3-5-9-19-6136-387-384-391-386-382-378-400-488-485-482-496-486-510-501-491-481-467-1,475-1,156-1,043-976-894-810-728-641-646-12-3311-901288495-11-310594436-178-2501-111-177-206-79-307-5-45-159-79-6-18-14,952-53-14,952-8,894-8,894-8-8,894-26-40-56-3,600-3,600-3,700-3,500-3,000-2,600-2,100-1,700-1,300-1,000-800-600
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
67,756
67,845
69,394
69,425
69,502
70,315
70,898
72,373
90,287
90,343
90,498
98,835
99,027
99,188
99,342
99,472
133,780
133,983
134,128
134,283
134,477
134,744
134,715
134,885
137,113
141,147
141,266
144,776
144,836
144,894
144,952
147,915
151,222
151,987
152,024
152,040
157,341
199,475
200,665
224,149
224,282
0
0
0
0
0
0
0
0
0
0
0000000000224,282224,149200,665199,475157,341152,040152,024151,987151,222147,915144,952144,894144,836144,776141,266141,147137,113134,885134,715134,744134,477134,283134,128133,983133,78099,47299,34299,18899,02798,83590,49890,34390,28772,37370,89870,31569,50269,42569,39467,84567,756000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
16,300
26,600
78,400
79,000
79,500
80,700
81,200
81,700
82,100
600
1,400
2,200
85,538
85,692
87,917
0
89,164
109,646
130,592
0
138,860
163,406
163,481
148,791
197,552
198,449
199,004
226,279
299,860
300,046
301,629
301,811
370,702
370,827
370,180
384,629
501,284
506,117
511,584
527,992
530,389
533,297
536,245
538,070
540,403
541,433
542,422
542,930
56,167
56,657
57,862
57,935
65,096
65,870
66,067
66,048
66,193
68,912
69,320
69,861
69,906
69,993
70,816
71,408
72,859
90,773
90,825
90,983
99,323
99,427
99,566
99,724
99,858
134,171
134,367
134,515
134,283
134,477
134,744
134,715
134,885
137,113
141,147
141,266
145,183
145,234
144,894
144,952
148,294
151,598
152,368
152,391
152,410
157,685
199,735
200,665
224,402
224,494
224,386
224,505
224,672
224,844
224,941
225,061
225,265
225,452
225,606
225,747
225,747225,606225,452225,265225,061224,941224,844224,672224,505224,386224,494224,402200,665199,735157,685152,410152,391152,368151,598148,294144,952144,894145,234145,183141,266141,147137,113134,885134,715134,744134,477134,283134,515134,367134,17199,85899,72499,56699,42799,32390,98390,82590,77372,85971,40870,81669,99369,90669,86169,32068,91266,19366,04866,06765,87065,09657,93557,86256,65756,167542,930542,422541,433540,403538,070536,245533,297530,389527,992511,584506,117501,284384,629370,180370,827370,702301,811301,629300,046299,860226,279199,004198,449197,552148,791163,481163,406138,8600130,592109,64689,164087,91785,69285,5382,2001,40060082,10081,70081,20080,70079,50079,00078,40026,60016,300



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-111
Gross Profit-111-111
 
Operating Income (+$)
Gross Profit-111
Operating Expense-7,296
Operating Income-7,296-7,407
 
Operating Expense (+$)
Research Development1,013
Selling General Administrative6,283
Selling And Marketing Expenses0
Operating Expense7,2967,296
 
Net Interest Income (+$)
Interest Income1,830
Interest Expense-0
Other Finance Cost-0
Net Interest Income1,830
 
Pretax Income (+$)
Operating Income-7,296
Net Interest Income1,830
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-5,339-9,253
EBIT - interestExpense = -7,296
-5,450
-5,339
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-7,296-5,339
Earnings Before Interest and Taxes (EBITDA)-7,296
 
After tax Income (+$)
Income Before Tax-5,339
Tax Provision-0
Net Income From Continuing Ops-5,424-5,339
Net Income-5,339
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses7,296
Total Other Income/Expenses Net1,957-1,830
 

Technical Analysis of ARCA Biopharma Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of ARCA Biopharma Inc. The general trend of ARCA Biopharma Inc is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine ARCA Biopharma Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ARCA Biopharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 3.88.

The bearish price targets are: 2.6999 > 2.3943 > 2.3199.

Tweet this
ARCA Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ARCA Biopharma Inc. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ARCA Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ARCA Biopharma Inc. The current macd is 0.40517385.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the ARCA Biopharma Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for ARCA Biopharma Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the ARCA Biopharma Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
ARCA Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartARCA Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ARCA Biopharma Inc. The current adx is 59.97.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy ARCA Biopharma Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
ARCA Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ARCA Biopharma Inc. The current sar is 3.00483411.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
ARCA Biopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ARCA Biopharma Inc. The current rsi is 79.77. The current phase is Overbought in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Overbought in bull market: Short-term excessive buying, potential for pullback. Consider taking profits, be cautious of potential correction. -1
  • Trending up: The RSI is trending up. +1
ARCA Biopharma Inc Daily Relative Strength Index (RSI) ChartARCA Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ARCA Biopharma Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the ARCA Biopharma Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
ARCA Biopharma Inc Daily Stochastic Oscillator ChartARCA Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ARCA Biopharma Inc. The current cci is 67.46.

ARCA Biopharma Inc Daily Commodity Channel Index (CCI) ChartARCA Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ARCA Biopharma Inc. The current cmo is 59.82.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
ARCA Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartARCA Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ARCA Biopharma Inc. The current willr is -21.91880908.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that ARCA Biopharma Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
ARCA Biopharma Inc Daily Williams %R ChartARCA Biopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ARCA Biopharma Inc.

ARCA Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ARCA Biopharma Inc. The current atr is 0.20213168.

ARCA Biopharma Inc Daily Average True Range (ATR) ChartARCA Biopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ARCA Biopharma Inc. The current obv is 80,010,275.

ARCA Biopharma Inc Daily On-Balance Volume (OBV) ChartARCA Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ARCA Biopharma Inc. The current mfi is 96.01.

The long score for the Money Flow Index (MFI) is 2/2.
The longshort score for the Money Flow Index (MFI) is 2/(-2 +2).

  • MFI > 50: +1
  • MFI > 80: +1
ARCA Biopharma Inc Daily Money Flow Index (MFI) ChartARCA Biopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ARCA Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-24MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

ARCA Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ARCA Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5079.768
Ma 20Greater thanMa 502.683
Ma 50Greater thanMa 1002.074
Ma 100Greater thanMa 2001.889
OpenGreater thanClose3.260
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of ARCA Biopharma Inc with someone you think should read this too:
  • Are you bullish or bearish on ARCA Biopharma Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about ARCA Biopharma Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ARCA Biopharma Inc

I send you an email if I find something interesting about ARCA Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about ARCA Biopharma Inc.

Receive notifications about ARCA Biopharma Inc in your mailbox!